1文献来源Yue DS,Xu SD,Wang Q,et al.Erlotinib versus Vinorelbine plus Cisplatin as adjuvant therapy in Chinese patients with stage Ⅲ A EGFR mutation-positive non-small-cell lung cancer(EVAN):A randomised,open-label,ph...1文献来源Yue DS,Xu SD,Wang Q,et al.Erlotinib versus Vinorelbine plus Cisplatin as adjuvant therapy in Chinese patients with stage Ⅲ A EGFR mutation-positive non-small-cell lung cancer(EVAN):A randomised,open-label,phase 2 trial[J].Lancet Respir Med,2018,6(11):863-873.2证据水平1b。3背景尽管辅助化疗可能使部分ⅢA期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者获得生存获益,但更应探索耐受性优于辅助化疗的替代治疗,在增加生存获益的同时减少治疗相关的毒性。这一目标在Ⅲ期NSCLC中尤其重要,因为Ⅲ期NSCLC的预后较差,对辅助治疗的选择几乎没有共识。展开更多
文摘1文献来源Yue DS,Xu SD,Wang Q,et al.Erlotinib versus Vinorelbine plus Cisplatin as adjuvant therapy in Chinese patients with stage Ⅲ A EGFR mutation-positive non-small-cell lung cancer(EVAN):A randomised,open-label,phase 2 trial[J].Lancet Respir Med,2018,6(11):863-873.2证据水平1b。3背景尽管辅助化疗可能使部分ⅢA期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者获得生存获益,但更应探索耐受性优于辅助化疗的替代治疗,在增加生存获益的同时减少治疗相关的毒性。这一目标在Ⅲ期NSCLC中尤其重要,因为Ⅲ期NSCLC的预后较差,对辅助治疗的选择几乎没有共识。
